Armata Pharmaceuticals shares are trading higher after the company announced the FDA has cleared the company's investigational new drug application to initiate Phase 1b/2a clinical trial of lead candidate SP-PS02 in Pseudomonas aeruginosa infections.

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!